secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001528287-22-000004
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace reports 2021 revenue $45.2M (+10% YoY), Q4 net loss $10.7M
--------------------------------------------------------------------

- Full-year initial implant revenue $33.7M (+20% YoY); replacement revenue $11.5M (-12% YoY).
- Q4 total revenue $11.0M (+2% YoY); net loss $10.7M vs $4.6M loss in Q4 2020.
- FDA approved IDE for pivotal study in drug-resistant primary generalized epilepsy.
- 2022 guidance: full-year revenue $45-48M, initial implant revenue $39-42M.
- Cash and marketable securities $115.6M; long-term borrowings $49.8M as of Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828722000004/0001528287-22-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828722000004/npce-20220310.htm
  HTML page:      https://secwatch.observer/filing/0001528287-22-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer